Leptin’s Role in Lipodystrophic and Nonlipodystrophic Insulin-Resistant and Diabetic Individuals
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as meta- bolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mel- litus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin’s contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes. (Endocrine Reviews 34: 377– 412, 2013)
Leptin is an adipocyte-secreted hormone that has been proposed to regulate energy homeostasis as well as meta- bolic, reproductive, neuroendocrine, and immune functions. In the context of open-label uncontrolled studies, leptin administration has demonstrated insulin-sensitizing effects in patients with congenital lipodystrophy associated with relative leptin deficiency. Leptin administration has also been shown to decrease central fat mass and improve insulin sensitivity and fasting insulin and glucose levels in HIV-infected patients with highly active antiretroviral therapy (HAART)-induced lipodystrophy, insulin resistance, and leptin deficiency. On the contrary, the effects of leptin treatment in leptin-replete or hyperleptinemic obese individuals with glucose intolerance and diabetes mel- litus have been minimal or null, presumably due to leptin tolerance or resistance that impairs leptin action. Similarly, experimental evidence suggests a null or a possibly adverse role of leptin treatment in nonlipodystrophic patients with nonalcoholic fatty liver disease. In this review, we present a description of leptin biology and signaling; we summarize leptin’s contribution to glucose metabolism in animals and humans in vitro, ex vivo, and in vivo; and we provide insights into the emerging clinical applications and therapeutic uses of leptin in humans with lipodystrophy and/or diabetes. (Endocrine Reviews 34: 377– 412, 2013)
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
406 Moon et al Effects of Leptin on Glucose Metabolism Endocrine Reviews, June 2013, 34(3):377–412
obesity-resistance. Am J Physiol Endocrinol Metab. 2008;
295:E356–E367.
96. Tanaka T, Masuzaki H, Yasue S, et al. Central melanocortin
signaling restores skeletal muscle AMP-activated
protein kinase phosphorylation in mice fed a high-fat diet.
Cell Metab. 2007;5:395–402.
97. Saha AK, Xu XJ, Balon TW, Brandon A, Kraegen EW,
Ruderman NB. Insulin resistance due to nutrient excess: Is
it a consequence of AMPK downregulation? Cell Cycle.
2011;10:3447–3451.
98. Grisouard J, Dembinski K, Mayer D, Keller U, Müller B,
Christ-Crain M. Targeting AMP-activated protein kinase
in adipocytes to modulate obesity-related adipokine production
associated with insulin resistance and breast cancer
cell proliferation. Diabetol Metab Syndr. 2011;3:16.
99. Minokoshi Y, Kim YB, Peroni OD, et al. Leptin stimulates
fatty-acid oxidation by activating AMP-activated protein
kinase. Nature. 2002;415:339–343.
100. Nascimento AF, Luvizotto RA, Leopoldo AS, et al. Longterm
high-fat diet-induced obesity decreases the cardiac
leptin receptor without apparent lipotoxicity. Life Sci.
2011;88:1031–1038.
101. Gunn RM, Hailes HC. Insights into the PI3-K-PKB-mTOR
signalling pathway from small molecules. J Chem Biol.
2008;1:49–62.
102. Cho JE, Kim YS, Park S, Cho SN, Lee H. Mycobacterium
tuberculosis-induced expression of leukotactin-1 is mediated
by the PI3-K/PDK1/Akt signaling pathway. Mol Cells.
2010;29:35–39.
103. Zhang Z, Song T, Jin Y, et al. Epidermal growth factor
receptor regulates MT1-MMP and MMP-2 synthesis in
SiHa cells via both PI3-K/AKT and MAPK/ERK pathways.
Int J Gynecol Cancer. 2009;19:998–1003.
104. Filiputti E, Rafacho A, Araújo EP, et al. Augmentation of
insulin secretion by leucine supplementation in malnourished
rats: possible involvement of the phosphatidylinositol
3-phosphate kinase/mammalian target protein of rapamycin
pathway. Metab Clin Exp. 2010;59:635–644.
105. Cui W, Li W, Han R, et al. PI3-K/Akt and ERK pathways
activated by VEGF play opposite roles in MPP()-induced
neuronal apoptosis. Neurochem Int. 2011;59:945–953.
106. Que J, Lian Q, El Oakley RM, Lim B, Lim SK. PI3 K/Akt/
mTOR-mediated translational control regulates proliferation
and differentiation of lineage-restricted RoSH stem
cell lines. J Mol Signal. 2007;2:9.
107. Wang Y, Yan W, Lu X, et al. Overexpression of osteopontin
induces angiogenesis of endothelial progenitor cells via
the av?3/PI3K/AKT/eNOS/NO signaling pathway in glioma
cells. Eur J Cell Biol. 2011;90:642–648.
108. Rodríguez A, Gómez-Ambrosi J, Catalán V, Fortuño A,
Frühbeck G. Leptin inhibits the proliferation of vascular
smooth muscle cells induced by angiotensin II through nitric
oxide-dependent mechanisms. Mediators Inflamm.
2010;1054–1089.
109. Rodríguez A, Catalán V, Gómez-Ambrosi J, et al. Insulinand
leptin-mediated control of aquaglyceroporins in human
adipocytes and hepatocytes is mediated via the PI3K/
Akt/mTOR signaling cascade. J Clin Endocrinol Metab.
2011;96:E586–E597.
110. Cheng SP, Yin PH, Hsu YC, et al. Leptin enhances migration
of human papillary thyroid cancer cells through the
PI3K/AKT and MEK/ERK signaling pathways. Oncol
Rep. 2011;26:1265–1271.
111. Samuel-Mendelsohn S, Inbar M, Weiss-Messer E, Niv-
Spector L, Gertler A, Barkey RJ. Leptin signaling and apoptotic
effects in human prostate cancer cell lines. Prostate.
2011;71:929–945.
112. Barazzoni R, Zanetti M, Bosutti A, et al. Moderate caloric
restriction, but not physiological hyperleptinemia per se, enhances
mitochondrial oxidative capacity in rat liver and skeletal
muscle–tissue-specific impact on tissue triglyceride content
and AKT activation. Endocrinology. 2005;146:2098–
2106.
113. Fang X, Fetros J, Dadson KE, Xu A, Sweeney G. Leptin
prevents the metabolic effects of adiponectin in L6 myotubes.
Diabetologia. 2009;52:2190–2200.
114. Ernst MB, Wunderlich CM, Hess S, et al. Enhanced Stat3
activation in POMC neurons provokes negative feedback
inhibition of leptin and insulin signaling in obesity. J Neurosci.
2009;29:11582–11593.
115. Shetty GK, Matarese G, Magkos F, et al. Leptin administration
to overweight and obese subjects for 6 months increases
free leptin concentrations but does not alter circulating
hormones of the thyroid and IGF axes during weight
loss induced by a mild hypocaloric diet. Eur J Endocrinol.
2011;165:249–254.
116. Mirshamsi S, Laidlaw HA, Ning K, et al. Leptin and insulin
stimulation of signalling pathways in arcuate nucleus neurones:
PI3K dependent actin reorganization and KATP
channel activation. BMC Neurosci. 2004;5:54.
117. Hill JW, Elias CF, Fukuda M, et al. Direct insulin and leptin
action on pro-opiomelanocortin neurons is required for
normal glucose homeostasis and fertility. Cell Metab.
2010;11:286–297.
118. Al-Qassab H, Smith MA, Irvine EE, et al. Dominant role of
the p110 isoform of PI3K over p110 in energy homeostasis
regulation by POMC and AgRP neurons.Cell Metab.
2009;10:343–354.
119. Sasaki T, Kitamura T. Roles of FoxO1 and Sirt1 in the central
regulation of food intake. Endocr J. 2010;57:939–946.
120. Wang RH, Kim HS, Xiao C, Xu X, Gavrilova O, Deng CX.
Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling
and results in hyperglycemia, oxidative damage, and insulin
resistance. J Clin Invest. 2011;121:4477–4490.
121. Gu Y, Lindner J, Kumar A, Yuan W, Magnuson MA. Rictor/mTORC2
is essential for maintaining a balance between
-cell proliferation and cell size. Diabetes. 2011;60:
827–837.
122. Cypess AM, Zhang H, Schulz TJ, et al. Insulin/IGF-I regulation
of necdin and brown adipocyte differentiation via
CREB- and FoxO1-associated pathways. Endocrinology.
2011;152:3680–3689.
123. Coope A, Milanski M, Araújo EP, et al. AdipoR1 mediates
the anorexigenic and insulin/leptin-like actions of adiponectin
in the hypothalamus. FEBS Lett. 2008;582:
1471–1476.
124. Reiter CE, Kim JA, Quon MJ. Green tea polyphenol epigallocatechin
gallate reduces endothelin-1 expression and
secretion in vascular endothelial cells: roles for
AMP-activated protein kinase, Akt, and FOXO1. Endocrinology.
2010;151:103–114.
125. Iskandar K, Cao Y, Hayashi Y, et al. PDK-1/FoxO1 path-
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 10 June 2014. at 01:44 For personal use only. No other uses without permission. . All rights reserved.
Change language